Company Profile
Merck Stock Price, News & Catalysts
- Ticker:
- MRK
- Exchange:
- NYSE
- Sector:
- Oncology, Immunotherapy, Vaccines
- Location:
- United States
Stock performance
143.81 USD (-1.03%)
Close
Last updated: October 1, 2026
286B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, MRK closed down 1.03% at $143.81. No new same-company headline was identified in the current news window.
Company overview
Diversified Human and Animal Health Company
Merck, known as MSD outside the United States and Canada, is a global biopharmaceutical company with businesses in prescription medicines, vaccines, and animal health. Its human-health research spans oncology, infectious disease, vaccines, cardiometabolic and respiratory disease, immunology, neuroscience, and ophthalmology.
Oncology and the KEYTRUDA Franchise
Oncology is anchored by KEYTRUDA and subcutaneous KEYTRUDA QLEX, which are used across a broad range of solid tumors and hematologic malignancies. Merck is extending the franchise through earlier-stage treatment, perioperative regimens, and combinations with antibody-drug conjugates and targeted therapies. Its broader oncology pipeline includes sacituzumab tirumotecan, the personalized cancer vaccine intismeran autogene, KRAS inhibitor calderasib, and BCR::ABL1 inhibitor MK-4208.
Vaccines and Infectious Diseases
Merck has a large vaccine franchise spanning human papillomavirus, pneumococcal disease, respiratory syncytial virus, and other infectious diseases. The HIV portfolio combines approved daily treatment with investigational weekly and monthly approaches, including once-weekly islatravir and lenacapavir and once-monthly oral PrEP candidate alimatravir.
Cardiometabolic and Respiratory Medicines
The cardiometabolic portfolio includes WINREVAIR for pulmonary arterial hypertension and LIPFENDRA, an oral PCSK9 inhibitor for hypercholesterolemia. The acquisition of Verona Pharma added OHTUVAYRE for chronic obstructive pulmonary disease, expanding Merck's presence in respiratory medicine alongside a pipeline of cardiovascular and metabolic programs.
Immunology Pipeline
Merck is developing tulisokibart, an anti-TL1A antibody, across ulcerative colitis and other immune-mediated diseases. The program is part of a broader effort to build an immunology franchise through internally developed biologics and externally sourced assets that target inflammatory pathways with potential applications across gastrointestinal, dermatologic, and systemic autoimmune disorders.
Animal Health Business
Merck Animal Health markets medicines, vaccines, identification technologies, and health-management products for livestock and companion animals. The business provides an additional source of diversification and has expanded through acquisitions such as TARGAN, which added automated poultry vaccination and biodevice capabilities.
Future catalysts
- Planned global regulatory submissions for the once-weekly oral islatravir/lenacapavir HIV treatment regimen following positive Phase 3 ISLEND-1 and ISLEND-2 results.
- Presentation of full Phase 2 results for tulisokibart in hidradenitis suppurativa at an upcoming medical meeting.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Merck (MRK)?
Merck (MRK) most recently closed at 143.81 USD, a -1.03% move versus the previous session.
What is the market cap of Merck (MRK)?
Merck currently has a market capitalization of 286B USD on BioPharmSignal.
What does Merck do?
Diversified Human and Animal Health Company Merck, known as MSD outside the United States and Canada, is a global biopharmaceutical company with businesses in prescription medicines, vaccines, and animal health. Its human-health research spans oncology, infectious disease, vaccines, cardiometabolic and respiratory disease, immunology, neuroscience, and...
On which exchange is MRK stock listed?
Merck (MRK) is associated with NYSE, United States, Oncology, Immunotherapy, Vaccines.
What is MK-4208?
Its broader oncology pipeline includes sacituzumab tirumotecan, the personalized cancer vaccine intismeran autogene, KRAS inhibitor calderasib, and BCR::ABL1 inhibitor MK-4208.
Which conditions is Merck targeting with MK-4208?
Merck is associated with oncology, cancer therapeutics, immunology based on its company overview and current catalyst commentary.
How does Merck describe recent progress with MK-4208?
Planned global regulatory submissions for the once-weekly oral islatravir/lenacapavir HIV treatment regimen following positive Phase 3 ISLEND-1 and ISLEND-2 results. Presentation of full Phase 2 results for tulisokibart in hidradenitis suppurativa at an upcoming medical meeting.
What is ISLEND-1?
Planned global regulatory submissions for the once-weekly oral islatravir/lenacapavir HIV treatment regimen following positive Phase 3 ISLEND-1 and ISLEND-2 results.